Stay updated on Nemtabrutinib in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Nemtabrutinib in Hematologic Malignancies Clinical Trial page.

Latest updates to the Nemtabrutinib in Hematologic Malignancies Clinical Trial page
- Check3 days agoChange DetectedAdded a centralized Locations section with state listings for study sites (Arizona, California, Colorado, Michigan, Minnesota, North Carolina, Ohio, Tennessee, Texas, Utah) and removed the old per-location pages for these states. Updated the revision to v3.3.3.SummaryDifference0.9%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page footer now shows Revision: v3.3.2, replacing Revision: v3.3.1. No content or study data changes are included.SummaryDifference0.0%

- Check32 days agoChange DetectedThe Publications section now clarifies that entries are provided voluntarily by the data submitter and may be auto-filled from PubMed. The revision note records v3.3.1, replacing the previous v3.2.0 wording.SummaryDifference0.1%

- Check40 days agoChange DetectedThe site-wide notice about potential delays due to a lapse in government funding at the top of the ClinicalTrials.gov page was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check54 days agoChange DetectedThe update appears to be minor UI adjustments and an updated timestamp, with core study details, eligibility criteria, dosing, endpoints, and locations unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check82 days agoChange Detected- Added a funding/status notice and updated to v3.2.0. - Removed the term ‘Richter syndrome’ and old version reference v3.1.0.SummaryDifference2%

Stay in the know with updates to Nemtabrutinib in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nemtabrutinib in Hematologic Malignancies Clinical Trial page.